CelLBxHealth plc (AIM:CLBX)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 15.06M -15.5% |
| Revenue (ttm) | 1.15M -56.1% |
| Net Income | -12.94M |
| EPS | -0.02 |
| Shares Out | 1.14B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 272,362 |
| Open | 1.325 |
| Previous Close | 1.325 |
| Day's Range | 1.325 - 1.345 |
| 52-Week Range | 0.850 - 7.995 |
| Beta | 0.41 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 7, 2026 |
About CelLBxHealth
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix platform, emables real-time multiomic insights from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company o... [Read more]
Financial Performance
In 2025, CelLBxHealth's revenue was 1.35 million, a decrease of -52.80% compared to the previous year's 2.86 million. Losses were -19.51 million, 37.1% more than in 2024.
Financial StatementsNews
CelLBxHealth Quarterly report: H1 2026
CelLBxHealth has published its H1 2026 quarterly earnings report on July 15, 2026.
CelLBxHealth Earnings Call Transcript: H2 2025
Revenues declined in 2025 due to slower commercial conversion, but major restructuring and new partnerships have positioned the company for a 50% revenue increase in 2026 and EBITDA breakeven by late 2028. Cash burn is significantly reduced, and the business is funded through Q2 2027.
CelLBxHealth Annual report: H2 2025
CelLBxHealth has published its H2 2025 annual report on June 22, 2026.
CelLBxHealth Annual report: H2 2025
CelLBxHealth has published its H2 2025 annual report on June 22, 2026.
CelLBxHealth Slides: H2 2025
CelLBxHealth has posted slides in relation to its H2 2025 quarterly earnings report, which was published on June 22, 2026.
CelLBxHealth Earnings release: Q1 2026
CelLBxHealth released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
CelLBxHealth Earnings release: Q4 2025
CelLBxHealth released its Q4 2025 earnings on January 16, 2026, summarizing the period's financial results.
CelLBxHealth Slides: Q4 2025
CelLBxHealth has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on January 16, 2026.
CelLBxHealth Transcript: Investor Update
A new leadership team is driving a focused commercialization strategy, restructuring operations, and targeting profitability by 2028. Strategic partnerships and a narrowed market focus aim to capitalize on the growing need for circulating tumor cell diagnostics, with significant cost reductions and value inflection points expected in the next 12-18 months.
CelLBxHealth Slides: Investor Update
CelLBxHealth has posted slides in relation to its latest quarterly earnings report, which was published on November 26, 2025.
CelLBxHealth Earnings Call Transcript: H1 2025
Commercial progress continued with three pharma contracts completed and a major medtech partnership signed, despite revenue declines from market headwinds. Cost controls reduced losses, and the cash runway extends into Q1 2026. NHS engagement and new clinical partnerships are expected to drive future growth.
CelLBxHealth Quarterly report: H1 2025
CelLBxHealth has published its H1 2025 quarterly earnings report on September 9, 2025.
CelLBxHealth Slides: H1 2025
CelLBxHealth has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 9, 2025.
Angle PLC Announces Parsortix study uncovers targets in TNBC patients
Parsortix system harvests intact CTCs for whole genomic sequencing identifying multiple druggable targets Study demonstrates ctDNA and CTCs can both be analysed using the same blood sample GUILDFORD, ...